News

Baxalta bets again on Kamada with lung transplant deal

Baxalta, the soon-to-spin-out pharma arm of Baxter, has expanded its relationship with Israel's Kamada, agreeing to co-fund a trial testing whether the company's top prospect can prevent lung transplant rejections.

Kite and bluebird join forces with some cutting-edge cancer tech

Immuno-oncology innovator Kite Pharma is joining gene therapy luminary bluebird bio to craft new treatments for HPV-related cancers, combining two high-profile technologies in hopes of developing targeted therapies.

Biotech billionaire Soon-Shiong steers immuno-oncology player Conkwest to $172.5M IPO

Patrick Soon-Shiong thinks he can beat CAR-Ts in the clinic. And after quietly taking control of a small biotech named Conkwest, the biotech billionaire is now floating a $172.5 million IPO in a sizzling hot market to raise new funds for the midstage program that lies ahead.

FierceBiotech Radio on GlaxoSmithKline rumors, Allergan's new identity and Axovant's IPO

FiercePharma's Carly Helfand and FierceBiotech's Damian Garde discuss the week's biggest news in biopharma, including buyout rumors surrounding GlaxoSmithKline, the new face of Allergan and a biotech IPO that's turning heads around the industry.

Amgen's migraine drug gains momentum in a crowded race

Amgen says that its experimental migraine drug boosted its response rate among patients over a full year of therapy, a little bit of an edge that could help it compete against a group of rivals now hustling ahead with pivotal studies.

Teva ratchets up its M&A pressure on Mylan with larger stake

Teva has upped its Mylan stake yet again--this time, passing a critical threshold that could help it pose a legal challenge to its generics rival.

Bayer plans to dial up its R&D budget on the hunt for new blockbusters

Bayer is gearing up to spend more than ever before on R&D this year, CEO Marijn Dekkers said, investing in innovation with hopes of pushing some promising therapies onto the market.

PureTech banks $171M in a London IPO to fund its biotech bets

Biotech startup engine PureTech pulled off a $171 million IPO on the London Stock Exchange, crossing the Atlantic to raise cash for its hybrid approach to venture investing.

Tekmira's Ebola drug comes up short in Phase II

Tekmira's in-development treatment for Ebola virus failed to move the needle in a midstage trial, leading the drugmaker to halt the study and sending its share value downward.

Lilly and Teva tout new migraine data amid a crowded race

Eli Lilly and Teva, racing with a pack of drugmakers with a new approach to treating migraines, said their respective injected therapies succeeded in midstage trials, setting the stage for pivotal studies.

Ex-AstraZeneca R&D chief Morrison takes helm of Syndax Pharmaceuticals

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Eric Sagonowsky (email) or...

Antibiotics biotech Nabriva shoots for a $92M IPO

Austrian drug developer Nabriva Therapeutics is plotting to make its way to Wall Street in a $92 million IPO, raising cash to support its pipeline of treatments for infectious diseases.

FierceBiotech Radio at #BIO2015

FierceBiotech Radio is back with a two-part special from the BIO conference in Philadelphia.

Video: Blazing a short path to an accelerated approval in oncology

At the 2015 BIO conference in Philadelphia, FierceBiotech Editor-in-Chief John Carroll moderates a discussion on the future of cancer R&D, featuring leaders from AstraZeneca, Juno Therapeutics, Merck, Johnson & Johnson and GlaxoSmithKline.

Woodford doubles down on Circassia, Servier in $130M cancer deal, French biotechs eye NY cash

In this week's EuroBiotech Report, Neil Woodford's fund got deeper into Circassia, pulled out of Sanofi and criticized GlaxoSmithKline for performing "poorly operationally." Servier scooped up regional rights to Taiho Pharmaceutical's refractory metastatic colorectal cancer drug in a $130 million (€115 million) deal. And more.

French biotech CEOs roll into New York with money on their minds

A phalanx of French biotechs rolled into New York this week for a meeting with life science investors. Among the 20 biotechs at the flesh-pressing festival were some laying the groundwork for IPOs on Nasdaq, including Eli Lilly-partnered diabetes player Adocia.

Synergy's clinical success fuels the M&A rumor mill

A Phase III victory for Synergy Pharmaceuticals' constipation drug has made the company an attractive takeout target, analysts say, with the acquisitive Valeant Pharmaceuticals a potential suitor.

Celyad, Chiasma hop aboard Europe to Nasdaq express in bid to raise $185M

Celyad and Chiasma have joined the growing list of European biotechs to barrel into Wall Street in search of dollars. The companies are aiming to raise a total of around $185 million (€164 million), a sum that will go toward a mix of late-phase trials and CAR-T R&D.

Biotech fledglings crowd into a still-sizzling market for IPOs

Boulder, CO-based Nivalis Therapeutics rode the hot market for biotech IPOs to a $77 million windfall, banking on a very early-stage cystic fibrosis effort that's looking to ride on the coattails of a new combo therapy from Vertex.

Upstart Aimmune bags a 'breakthrough' tag for its peanut allergy drug

Fresh off of changing its name and posting some positive clinical results, Aimmune Therapeutics has picked up the FDA's coveted breakthrough therapy designation for its peanut allergy treatment, promising a speedy regulatory process for the company's lead drug.